Evaluation of the Response of Itraconazole and Terbinafine Therapy in Subjects With Crohn's Disease

NCT05049525 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

16

Enrollment

OTHER

Sponsor class

Stopped Insufficient patient enrollment

Conditions

Crohn's Disease
Inflammatory Bowel Diseases

Interventions

DRUG: Itraconazole 400 mg/day and terbinafine 500 mg/day administered orally.
DRUG: Itraconazole's matching placebo 400 mg/day and terbinafine's matching placebo 500 mg/day administered orally.

Sponsor

Montreal Heart Institute